What is MBIO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MBIO?

P/E (TTM) is n/a and 52-week range is $0.41 to $1.85 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MBIO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MBIO?

The company profile lists net income (TTM) near $-3M, EPS (TTM) near $-0.46 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Mustang Bio Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Waltham, Massachusetts, US, 7.6M shares outstanding, ISIN US62818Q3020 when available from company profile and filing metadata.

Mustang Bio Inc (MBIO) Stock Analysis, Quote & Company Profile

Mustang Bio Inc

$MBIO

Health Care · Biotechnology

IR Run Scenarios

$0.40

-4.05%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company is headquartered in Waltham, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2017-08-22. The firm has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. The company is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. The company has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.

Employees

Website

www.mustangbio.com/

IPO

2017-08-22

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)